Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2492MR)

This product GTTS-WQ2492MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&FOLH1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001014986.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 2346
UniProt ID P07766; Q04609
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2492MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6239MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ5557MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ9501MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ15447MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ5152MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ5475MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ7954MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ3861MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-089
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW